CapeOx Clinical Trials

5 actively recruiting trials across 1 location

▼ -1 trial since July 2026

Also known as: Capecitabine, Capecitabine and oxaliplatin, Oxaliplatin, Surgery

Pipeline

Phase 2: 3Phase 3: 2

Top Sponsors

GlaxoSmithKline2
Ruijin Hospital1
Fudan University1
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1

Indications

Cancer5
Neoplasms, Colon2
Rectal Cancer2
Colonic Neoplasms1
Colon Adenocarcinoma1

Other4 trials

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Phase 2

HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

Phase 2

Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

Phase 3

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

Phase 2

Tucson, Arizona1 trial

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

GSK Investigational Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.